NYSE American - Nasdaq Real Time Price USD

China Pharma Holdings, Inc. (CPHI)

2.3001

+0.1401

+(6.46%)

As of 2:02:38 PM EDT. Market Open.

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401.

PR Newswire last month

CPHI
+6.46%
China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced successful completion of all redemptions under its Convertible Promissory Note agreement (the "Convertible Promissory Note") with Streeterville Capital, LLC as of December 11, 2024. This marks a significant step in strengthening the company's financial position and reflects its c

PR Newswire 4 months ago

CPHI
+6.46%
China Pharma Announces the Entry of "At-The-Market" Equity Offering

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing").

PR Newswire 5 months ago

CPHI
+6.46%
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China.

PR Newswire 8 months ago

CPHI
+6.46%

Performance Overview

Return	CPHI	S&P 500 (^GSPC)
YTD	+0.00%	+1.05%
1-Year	-36.11%	+11.97%
3-Year	-98.16%	+52.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

China Pharma Holdings, Inc. (CPHI)

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

China Pharma Announces the Entry of "At-The-Market" Equity Offering

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025

Performance Overview